ChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responses
Vaccine·
- DOI
- 10.1016/j.vaccine.2026.128951
- PMID
- 42472497
- PMCID
- —
- OpenAlex
- W7169779515
- Study type
- Journal article
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
Tracking extended safety outcomes in vaccinated populations aligns with established priorities for evaluating long-term product performance in preventive healthcare frameworks.
Structured evidence summary
Research question
The investigation aims to evaluate the extended safety profile and immunological outcomes of the ChAdOx1 nCoV-19 vaccine by tracking individuals who initially participated in early clinical trials.
Study design
Researchers conducted a prospective observational follow-up that monitored serious adverse events and predefined special interest events according to established classification standards.
Population and setting
The cohort comprised 4,470 individuals recruited between September 2021 and April 2022, predominantly located in the United Kingdom, with a median age of fifty years and a majority of female participants.
Main findings
During a median observation period of approximately eleven months, investigators documented one hundred seventy-four serious adverse events and seventy-one special interest events across one hundred ninety-five individuals, alongside five fatalities. Limited immunological assessments indicated a general rise in antibody concentrations directed at the viral spike protein.
Public-health relevance
Tracking extended safety outcomes in vaccinated populations aligns with established priorities for evaluating long-term product performance in preventive healthcare frameworks.
Important limitations
Immunological measurements were restricted to a minor portion of the overall cohort, and the authors acknowledge that additional post-marketing observation is necessary to fully characterize long-term risks.
GIDS interpretation
This publication offers contextual background regarding prolonged safety observation and immunological trends within a defined cohort. The findings serve as a reference for understanding historical product characteristics without indicating correspondence to any active epidemiological tracking system.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 12 auditable classifier relationships to diseases, places, topics, and study design.